Thomas A. d’Amato

TL;DR: Anatomic segmentectomy outcomes compare favorably with standard lobectomy for stage I NSCLC and Margin/tumor ratios exceeding 1 were associated with a significant reduction in recurrence rates compared with ratios of less than 1, which should be considered as primary therapy when such margins are not obtainable with segmentectomy in the good-risk patient.

TL;DR: High VEGF expression, tumor size, and angiolymphatic invasion emerged as three independent factors predicting worsening prognosis using multivariate analysis.

TL;DR: Minimally invasive resection of benign esophageal tumors is technically safe and associated with a shorter length of stay compared with open approaches, and the subsequent development of reflux may be related to the esophagal myotomy required for resection.

TL;DR: Review of early data suggests that intraoperative 125I vicryl mesh brachytherapy in high-risk Stage I NSCLC is potentially effective and well tolerated, with no significant decline in measurable pulmonary function studies and no increase in postoperative complications.

TL;DR: Chemotherapy resistance is prevalent among NSCLC clinical cell cultures, and the use of viable tumor culture for in vitro chemoresistance testing should be considered when formulating a plan of adjuvant therapy for resected NSCLCs.